Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03952143 |
| Consolidated Lead Sponsor | Eli Lilly and Company |
| Therapeutic Condition Cohort | Endocrinology, Obesity, and Metabolic |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 628 participants (ACTUAL) |
| Registered Start Date | 2019-05-27 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Tianjin Medical University General Hospital | Tianjin, China | Open Hospital Dossier -> |
| Shengjing hospital of China medical university | Shenyang, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.